Differential expression of mTOR signalling components in drug resistance in ovarian cancer.
about
DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagyElucidating the role of DEPTOR in Alzheimer's disease.Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistanceOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Placental DEPTOR as a stress sensor during pregnancy.Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic applicationAn evolving role for DEPTOR in tumor development and progression.DEPTOR ubiquitination and destruction by SCF(β-TrCP).Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation.Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses.microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin.DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinaseThe human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone.Triggering autophagic cell death with a di-manganese(II) developmental therapeuticProteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival.Identification of novel cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.Prognostic and clinicopathological significance of DEPTOR expression in cancer patients: a meta-analysis
P2860
Q28251037-D9974A3F-CD34-4FD5-91C0-A32143456B98Q34350366-2CB1A262-C6AA-4B95-A816-8C5DE17E13A5Q34550042-C528DB81-8CC2-4C45-BCB7-FD914AF900F6Q35837949-A27B1FCA-A5F2-48B6-9166-23CA0EC8D045Q36047085-906039AE-BE3A-4548-B1FE-60D75B34B164Q36062128-D4489F12-9554-4E34-B4DE-08B672A3EB9AQ36062133-8A74EE3F-BE03-47FD-8035-E20195268579Q36200219-A8DA6386-A404-4D95-8D8C-667296FE7BE6Q36965018-934F1709-EFCA-4B1C-8758-7EF9726AA417Q36992167-65E2C3DA-B030-4A9E-A68A-82FA31EA2988Q37151705-0B5D8DBA-26EF-4138-AEBF-E2E2A1717D64Q37211707-112A1E3A-DE56-49B5-8BEB-BFDC3161BC10Q37269248-D8D85E3E-41C4-4991-8127-A5F67DA495CEQ37374462-908ED791-C353-4137-A1EF-218FB6F44D29Q37670137-E156C787-FEA2-44BF-B06C-3D30C60886A5Q39658084-2225D778-9CEB-4890-8730-460300577511Q47416249-E4240CA9-8F0A-490A-A4E6-0A937BEE96B7Q49393542-465F5447-FFC5-41BF-84D5-7B806F8A5E21Q58720103-44BC925A-A819-4129-BFF9-DD7FD03A2069
P2860
Differential expression of mTOR signalling components in drug resistance in ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Differential expression of mTO ...... resistance in ovarian cancer.
@en
Differential expression of mTO ...... resistance in ovarian cancer.
@nl
type
label
Differential expression of mTO ...... resistance in ovarian cancer.
@en
Differential expression of mTO ...... resistance in ovarian cancer.
@nl
prefLabel
Differential expression of mTO ...... resistance in ovarian cancer.
@en
Differential expression of mTO ...... resistance in ovarian cancer.
@nl
P2093
P1433
P1476
Differential expression of mTO ...... g resistance in ovarian cancer
@en
P2093
Amanda Harvey
Anastasia Goumenou
Emmanouil Karteris
George Pados
Helen M Coley
P304
P407
P577
2010-09-01T00:00:00Z